LGALS9 and cancer: The immunomodulatory effects of Gal-9 were initially attributed to signaling via T-cell immunoglobulin and mucin domain-3 (TIM-3) [3], a prominent T-cell inhibitory receptor and a marker for T-cell exhaustion that is currently being evaluated as a target for antibody-based therapy in cancer [14].